OrigiMed is a medical science and technology company committed to developing new technologies and clinical applications for a wide range of cancer patients. By developing more comprehensive high-throughput detected method and using powerful bioinformatics analysis, we identify cancer specific molecular markers and genomic features to guide targeted or immune-therapy, ultimately aim to accelerate the development of cancer precision medicine in China.